COVID19 Clinical Trial
— COPCOVOfficial title:
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)
NCT number | NCT04303507 |
Other study ID # | VIR20001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 29, 2020 |
Est. completion date | March 22, 2022 |
Verified date | May 2022 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a double-blind, randomised, placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other persons at risk of contracting COVID-19, who can be followed reliably for 5 months. The initial aim was to recruit 40,000 participants and we predict an average of 400-800 participants per site in 50-100 sites. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation), or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155mg tablets for a 60kg subject), followed by 155 mg daily (250mg chloroquine phosphate salt/ 200mg hydroxychloroquine sulphate) will be taken for 3 months. If the participant is diagnosed with COVID-19, they will take continue to take the study medication until: - 90 days after enrolment (i.e., completion of kit) - hospitalised due to COVID-19 disease (i.e., not for quarantine purposes) in which case they will stop, or - advised to stop by their healthcare professional for other reasons Episodes of symptomatic respiratory illness, including symptomatic COVID-19, and clinical outcomes will be recorded in the Case Record Form during the follow-up period. This study is funded by Wellcome Trust Grant reference 221307/Z/20/Z.
Status | Completed |
Enrollment | 4652 |
Est. completion date | March 22, 2022 |
Est. primary completion date | March 22, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility | Study Participants The study population is adult healthcare workers and other persons defined by the site investigator at risk of contracting COVID-19. Inclusion Criteria 1. Participant is willing and able to give informed consent for participation in the study and agrees with the study and its conduct 2. Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals 3. Adults (exact age is dependent on countries) less than 70 years old at the time of consent 4. Not previously diagnosed with COVID-19 5. Not currently symptomatic with an ARI 6. Participant is a healthcare worker or is a person at risk of contracting COVID-19. 7. Possesses an internet-enabled smartphone (Android or iOS) Exclusion Criteria: 1. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines 2. Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known creatinine clearance < 10 ml/min 3. Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines, or history of these medications within the previous 7 days 4. Taking prohibited medications 5. Known retinal disease 6. Inability to be followed up for the trial period 7. Known prolonged QT syndrome (however ECG is not required at baseline) 8. Known pregnancy or women who are actively trying to become pregnant 9. Prior diagnosis of porphyria 10. Previously received any dose of COVID-19 vaccine The investigator may consult the physician's guidance documents for any further questions regarding eligibility of potential participants. Prohibited medications for the purpose of study enrollment include: - Antiarrhythmic medications: digoxin, amiodarone, sotalol, flecainide - Antiparasitic/malarial agents: mefloquine, halofantrine, praziquantel - Antibiotics: levofloxacin, moxifloxacin, ciprofloxacin, azithromycin, clarithromycin, erythromycin - Antifungal drugs: fluconazole, ketoconazole, itraconazole, terfenadine - Psychoactive drugs: lithium, quetiapine, chlorpromazine, thioridazine, ziprasidone, haloperidol, droperidol, methadone - Migraine treatment: sumatriptan - Antihistamines: astemizole - Antiemetics: prochlorperazine, metoclopramide - Cancer treatments: abiraterone, dabrafenib, dacomitinib, enzalutamide, idelalisib, mitotane - Other specific drugs: ciclosporin, conivaptan, agalsidase alfa or beta, mifepristone, stiripentol PrincipaI Investigators will also be directed to crediblemeds.org to check other agents that may prolong QT interval |
Country | Name | City | State |
---|---|---|---|
Benin | Centre Hospitalier et Universitaire de Zone Abomey-Calavi | Abomey-Calavi | |
Benin | Hospital De Zone Allada | Allada | |
Côte D'Ivoire | University Hospital Center of Angre | Abidjan | |
Côte D'Ivoire | University Hospital Center of Bouake | Bouake | |
Indonesia | Bunda Thamrin Hospital | Medan | North Sumatra |
Indonesia | Murni Teguh Memorial Hospital | Medan | North Sumatra |
Indonesia | Airlangga University Hospital (UNAIR) | Surabaya | East Java |
Indonesia | Husada Utama Hospital | Surabaya | East Java |
Indonesia | Sardjito Hospital | Yogyakarta | |
Kenya | Fountain Healthcare Hospital | Eldoret | |
Kenya | Mbagathi County Hospital | Nairobi | |
Mali | Hospital Of Mali | Bamako | |
Mali | The Bamako Hospital of Dermatology | Bamako | |
Nepal | B.P. Koirala Institute of Health Sciences | Dharan Bazar | |
Pakistan | The Aga Khan University Hospital | Karachi | |
Thailand | Faculty of Tropical Medicine, Mahidol University | Bangkok | |
United Kingdom | Birmingham & Solihull Mental Health NHS Trust | Birmingham | |
United Kingdom | Brighton and Sussex University Hospitals NHS Trust | Brighton | |
United Kingdom | University Hospitals Coventry and Warwickshire NHS Trust | Coventry | |
United Kingdom | Rotherham, Doncaster And South Humber NHS Foundation Trust | Doncaster | |
United Kingdom | The Dudley Group NHS Foundation Trust | Dudley | West Midlands |
United Kingdom | University Hospitals Of Morecambe Bay NHS Foundation Trust | Kendal | Cumbria |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | Oxford University Hospital NHS Foundation Trust | Oxford | |
Zambia | Zambart | Lusaka |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
Benin, Côte D'Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Thailand, United Kingdom, Zambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Genetic loci and levels of biochemical components will be correlated with frequency of COVID-19, ARI and disease severity. | Genetic loci and levels of biochemical components will be correlated with frequency of COVID-19, Acute Respiratory Infection and disease severity. | Approximately 90 days | |
Other | Assess the impact of chloroquine or hydroxychloroquine prophylaxis on number of days lost to work during the pandemic. | Number of days lost to work in relation to the treatment arm | Approximately 90 days | |
Other | Assess the impact of chloroquine or hydroxychloroquine prophylaxis on healthcare costs | The trial will collect data on monetary costs associated with the use of healthcare resources and determine the effects between treatment groups. | Approximately 90 days | |
Other | Assess the impact of chloroquine or hydroxychloroquine prophylaxis on quality of life measures using the quality of life questionnaire (EQ-5D-3L) | The trial will collect data on health-related quality of life using the quality of life questionnaire (EQ-5D-3L) to determine the effects between treatment groups. | Approximately 90 days | |
Primary | Number of symptomatic COVID-19 infections | Number of symptomatic COVID-19 infections will be compared between the chloroquine or hydroxychloroquine and placebo groups | Approximately 90 days | |
Secondary | Symptoms severity of COVID-19 | Symptoms severity of COVID-19 will be compared between the two groups using a respiratory severity score. | Approximately 90 days | |
Secondary | Number of asymptomatic cases of COVID-19 | Number of asymptomatic cases of COVID-19 will be determined by comparing serology in all participants at time of enrolment and at the end of follow up. | Approximately 90 days | |
Secondary | Number of symptomatic acute respiratory illnesses | Number of symptomatic acute respiratory illnesses will be compared between the chloroquine or hydroxychloroquine and placebo groups. | Approximately 90 days | |
Secondary | Severity of symptomatic acute respiratory illnesses | Severity of symptomatic acute respiratory illnesses will be compared between the chloroquine or hydroxychloroquine and placebo groups. | Approximately 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |